COMPASS Pathways Plc American Depository Shares (CMPS) vs Eton Pharmaceuticals (ETON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed COMPASS Pathways Plc American Depository Shares (CMPS) over the past year, gaining 159.5% versus a gain of 87.3%. Over five years, ETON leads with a +953.4% price change compared with -63.7% for CMPS. COMPASS Pathways Plc American Depository Shares is the larger company by market cap ($1.62 billion vs $1.57 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPS | ETON |
|---|---|---|
| Share price | $11.69 | $54.88 |
| Market cap | $1.62B | $1.57B |
| 1-day change | +1.12% | +0.20% |
| YTD return | +69.42% | +224.54% |
| 1-year return | +87.34% | +159.48% |
| 5-year return | -63.72% | +953.36% |
| P/E ratio (TTM) | — | 137.20 |
| Forward P/E | — | 21.27 |
| EPS (TTM) | $-3.76 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.87 | $66.37 |
| 52-week low | $4.88 | $14.27 |
| Distance from 52-week high | -26.34% | -17.31% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +103.17% | +29.37% |
| Average volume | 3.13M | 603.39K |
| Shares outstanding | 138.48M | 28.58M |
| Employees | 156 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed CMPS by 72.1 percentage points over the past year.
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
CMPS vs ETON FAQ
Which is bigger, COMPASS Pathways Plc American Depository Shares or Eton Pharmaceuticals?
COMPASS Pathways Plc American Depository Shares (CMPS) is larger, with a market capitalization of $1.62B compared with $1.57B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, CMPS or ETON?
ETON returned +159.48% over the past 12 months, compared with +87.34% for CMPS (price return, excluding dividends). Past performance does not predict future results.
Are COMPASS Pathways Plc American Depository Shares and Eton Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.